XOMA (NASDAQ:XOMA) Upgraded at StockNews.com

StockNews.com upgraded shares of XOMA (NASDAQ:XOMA) from a sell rating to a hold rating in a research report released on Thursday morning.

Separately, HC Wainwright restated a “buy” rating and set a $123.00 price objective on shares of XOMA in a research note on Tuesday, January 7th.

XOMA Stock Down 1.9 %

XOMA stock opened at $26.76 on Thursday. The business has a 50 day moving average of $28.58 and a 200 day moving average of $28.05. The firm has a market cap of $315.23 million, a PE ratio of -7.69 and a beta of 0.92. XOMA has a twelve month low of $18.57 and a twelve month high of $35.00. The company has a quick ratio of 7.52, a current ratio of 7.52 and a debt-to-equity ratio of 1.28.

Insider Transactions at XOMA

In other XOMA news, CEO Owen Hughes sold 21,881 shares of XOMA stock in a transaction that occurred on Wednesday, November 13th. The shares were sold at an average price of $29.95, for a total value of $655,335.95. Following the completion of the sale, the chief executive officer now owns 34,979 shares of the company’s stock, valued at approximately $1,047,621.05. The trade was a 38.48 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Company insiders own 7.20% of the company’s stock.

Institutional Trading of XOMA

Hedge funds have recently bought and sold shares of the company. Ellsworth Advisors LLC purchased a new stake in shares of XOMA in the 3rd quarter worth $516,000. Barclays PLC increased its position in XOMA by 300.7% in the third quarter. Barclays PLC now owns 11,256 shares of the biotechnology company’s stock worth $298,000 after buying an additional 8,447 shares in the last quarter. Bank of New York Mellon Corp raised its stake in shares of XOMA by 3.2% in the second quarter. Bank of New York Mellon Corp now owns 62,656 shares of the biotechnology company’s stock worth $1,484,000 after buying an additional 1,968 shares during the period. State Street Corp lifted its position in shares of XOMA by 1.2% during the 3rd quarter. State Street Corp now owns 142,857 shares of the biotechnology company’s stock valued at $3,783,000 after buying an additional 1,754 shares in the last quarter. Finally, Rhumbline Advisers grew its stake in shares of XOMA by 16.0% during the 2nd quarter. Rhumbline Advisers now owns 9,695 shares of the biotechnology company’s stock valued at $230,000 after acquiring an additional 1,334 shares during the period. Hedge funds and other institutional investors own 95.92% of the company’s stock.

About XOMA

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.